Navigation Links
Mylan One of First to Launch Generic Version of Boniva®
Date:3/20/2012

PITTSBURGH, March 20, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ibandronate Sodium Tablets, 150mg. This product is the generic version of Roche's Boniva®, which is indicated for the treatment and prevention of osteoporosis in postmenopausal women.

Boniva® had U.S. sales of approximately $517 million for the 12 months ending Dec. 31, 2011, according to IMS Health. Mylan is shipping the product immediately.

Currently, Mylan has 173 ANDAs pending FDA approval representing $100.9 billion in annual sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $27.4 billion in annual brand sales, for the 12 months ending December 31, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Canada Receives Health Canada Approval for Generic Version of Crestor®
2. Mylan Continues to Pursue Damages and Injunction Against Sunovions Brovana® in Ongoing Litigation
3. Mylan Pharmaceuticals President Tony Mauro Elected Chairman of GPhA
4. Mylan Secures an Additional $300 Million of Committed Financing
5. Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year
6. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement
7. Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
8. Mylan Actively Addressing Shortage of Preservative-Free Methotrexate Injection
9. Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers
10. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
11. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Acsis Inc., the market leader for supply chain ... John DiPalo , Acsis, Chief Strategy Officer, has ... Executive 2015 Provider Pro to Know. The award ... help prepare their companies, and customers, supply chains for ... list of Provider Pros to Know is featured in ...
(Date:2/27/2015)... - La ... monitoraggio dell,infarto congestizio (CHF - Congestive Heart Failure) ...   Vectorious Medical Technologies, società ... il monitoraggio cardiaco destinato a pazienti affetti da ... concluso una raccolta di finanziamenti per 5 milioni ...
(Date:2/27/2015)... 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... its pro forma net operating loss (NOL) guidance and ... financial position.  Isis, significantly improved financial results were due ... in payments the Company received from its partners.  Isis, ... a nearly 60% improvement over its 2013 NOL of ...
Breaking Medicine Technology:Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17
... - Abraxis BioScience,Inc. (NASDAQ:ABBI), an integrated, ... pre-clinical studies that,provide evidence for chemotherapy ... (ABRAXANE(R) for Injectable,Suspension (paclitaxel protein-bound particles ... drugs like,bevacizumab (Avastin(R)) at the 98th ...
... LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis ... results from two pre-clinical studies that,support the ... rich in,cysteine) expression in cancer and Abraxis' ... Association for Cancer Research (AACR) Annual Meeting ...
Cached Medicine Technology:Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 2Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 3Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 4Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 5
(Date:3/1/2015)... (PRWEB) March 01, 2015 “ The Barrel ... monthly Tech Report, which takes a look at the latest ... Tropeano, the host of NewsWatch and a technology expert, conducted ... spiral adds flavor to drinks. , According to Home Distillation ... the best spirits. Well, there’s a pretty cool product that’ll ...
(Date:2/28/2015)... 2015 The MCA Youth Empowerment Conference ... one platform and gears towards the goal for a ... of group talks in smaller groups will be held ... Personal Development, Leadership, Entrepreneurship, Healthcare, Social and Volunteerism, Women ... Malaysian youths. , Young adults aged between ...
(Date:2/28/2015)... In a recent episode of SCI TV ... Athlete Development Services and Consultancy talks with Joshua ... development and player engagement during and after their careers. ... face and how off-field activities are a critical component ... in athlete development issues while in graduate school coaching ...
(Date:2/28/2015)... The Heart Fit Clinic started doing ... the machine. The Heart Fit Clinic is also selling ... franchise model. The goal is to scale the business ... To buy External Counterpulsation machines can be ... through this process and achieve the desired results. ...
(Date:2/28/2015)... 28, 2015 Mew and Company, a ... they now provide business consulting services in addition to ... tax planning and succession planning. Company finances are a ... professionals. On top of this, complex Canadian tax laws ... accounting. As a result, Mew and Company works to ...
Breaking Medicine News(10 mins):Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2
... According to an inquest heard, a patient was given a lethal ... than 100 hours in a week.// ,Dr Helen Pike, ... her. The patient, Tony Wright, 58 suffered a massive cardiac arrest ... in the hospital’s ICU. ,Once his wife heard about ...
... for a new study has shown that even few pounds overweight ... compared// to those who maintain the optimum weight. ... was conducted involving 500,000 people, which took into consideration their lifestyle ... , ,The study revealed that obese people carried ...
... costs as well as indirect costs for employers, ... Occupational and Environmental// Medicine, official publication of the ... ,Led by Dr. Gene Colice of ... a large insurance database to analyze costs associated ...
... a spurt in cases of diarrhea, nausea, and vomiting, which ... outbreak. ,A common infection at this time ... to have taken a virulent form. It would do good ... infection. It is important to wash hands well after the ...
... has found a way to reduce brain swelling, the most ... doctoral student Renée Turner in the Discipline of Pathology at ... brain seems to mimic a similar process in the skin, ... these are yet to be developed. ,“This potentially ...
... American and South African scientists working at the epicenter ... how the human immunodeficiency virus// (HIV) “exhausts” killer T ... found that HIV can simply “turn off” fully functional ... cells. In test tube studies, however, the scientists showed ...
Cached Medicine News:Health News:Sheer exhaustion makes a junior doc’ kill a patient! 2Health News:Sheer exhaustion makes a junior doc’ kill a patient! 3Health News:Insurance Data Show High Costs of Persistent Asthma 2Health News:How HIV "Exhausts" Killer T Cells 2Health News:How HIV "Exhausts" Killer T Cells 3Health News:How HIV "Exhausts" Killer T Cells 4
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With reinforced ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With reinforced ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With cast ...
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
Medicine Products: